HIV-specific T-cell induction
AssigneeBoard of Regents, The University of Texas System
InventorsK. Sastry, Ralph Arlinghaus, Pramod Nehete
Life of this patent
Estimating the term…
Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsK. Sastry, Ralph Arlinghaus, Pramod Nehete
Estimating the term…
This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.
1-74. (Cancelled)
A method of treating an HIV-infected human subject to reduce the likelihood that said subject will develop AIDS, the method comprising the steps of administering to said subject a pharmaceutically acceptable composition which delivers one or more peptides having peptide sequences selected from the group consisting of one or more of the following groups of peptide sequences:
The method of claim 44, wherein the plurality of peptide sequences delivered to said subject comprises at least five peptide sequences, one selected from each of the following five groups of peptide sequences:
Dependencies are inferred from the claim text.